NASDAQ:VRMLVermillion Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.05 -0.12 (-2.88 %) (As of 08/14/2020 10:11 AM ET) Add Compare Share Today's Range$4.00Now: $4.05▼$4.2050-Day Range$3.43MA: $4.14▼$5.2552-Week Range$0.35Now: $4.05▼$5.78Volume442,642 shsAverage Volume440,144 shsMarket Capitalization$394.38 millionP/E RatioN/ADividend YieldN/ABeta3.47 ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Vermillion. Previous Next 2.5 Community Rank Outperform VotesVermillion has received 204 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVermillion has received 204 “underperform” votes. (Add your “underperform” vote.)Community SentimentVermillion has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote “Outperform” if you believe VRML will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRML will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVermillion does not currently pay a dividend.Dividend GrowthVermillion does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vermillion insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of Vermillion is held by insiders.Percentage Held by InstitutionsOnly 18.09% of the stock of Vermillion is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vermillion is -24.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vermillion is -24.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVermillion has a P/B Ratio of 45.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRML Previous Symbol CUSIPN/A CIK926617 Webwww.vermillion.com Phone512-519-0400Debt Debt-to-Equity Ratio0.20 Current Ratio2.51 Quick Ratio2.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.54 million Price / Sales86.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book45.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-15,240,000.00 Net Margins-307.31% Return on Equity-155.25% Return on Assets-103.47%Miscellaneous Employees43 Outstanding Shares97,378,000Market Cap$394.38 million Next Earnings DateN/A OptionableOptionable $4.05 -0.12 (-2.88 %) (As of 08/14/2020 10:11 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VRML News and Ratings via Email Sign-up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Vermillion (NASDAQ:VRML) Frequently Asked Questions How has Vermillion's stock price been impacted by COVID-19 (Coronavirus)? Vermillion's stock was trading at $0.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRML stock has increased by 382.1% and is now trading at $4.05. View which stocks have been most impacted by COVID-19. How were Vermillion's earnings last quarter? Vermillion, Inc. (NASDAQ:VRML) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $1.14 million for the quarter. Vermillion had a negative return on equity of 155.25% and a negative net margin of 307.31%. View Vermillion's earnings history. Has Vermillion been receiving favorable news coverage? Media headlines about VRML stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vermillion earned a news sentiment score of 2.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Vermillion. Who are some of Vermillion's key competitors? Some companies that are related to Vermillion include Intellia Therapeutics (NTLA), Heska (HSKA), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Celldex Therapeutics (CLDX), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), ImmuCell (ICCC), Arca Biopharma (ABIO), Akers Biosciences (AKER) and Achieve Life Sciences (ACHV). View all competitors. What other stocks do shareholders of Vermillion own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vermillion investors own include CombiMatrix (CBMX), Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Idera Pharmaceuticals (IDRA), Opko Health (OPK), TrovaGene (TROV), Agenus (AGEN), Charter Communications (CHTR), Fluidigm (FLDM) and Gilead Sciences (GILD). Who are Vermillion's key executives? Vermillion's management team includes the following people: Ms. Valerie Barber Palmieri, CEO, Pres & Director (Age 58)Mr. Robert Harry Beechey CPA, Chief Financial Officer (Age 56)Mr. Chris Goulart, Sr. VP of Commercial Operations What is Vermillion's stock symbol? Vermillion trades on the NASDAQ under the ticker symbol "VRML." How do I buy shares of Vermillion? Shares of VRML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vermillion's stock price today? One share of VRML stock can currently be purchased for approximately $4.05. How big of a company is Vermillion? Vermillion has a market capitalization of $394.38 million and generates $4.54 million in revenue each year. Vermillion employs 43 workers across the globe. What is Vermillion's official website? The official website for Vermillion is www.vermillion.com. How can I contact Vermillion? Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected] This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
